Bringing the fundamentals into focus…
Back to Immunocore Holdings plc
How Immunocore Holdings plc stacks up
IMCR · against 448 other Healthcare companies of similar size
Valuation
29/ 100
Below the middle of the pack.
Ranked #316 of 449 · scores higher than 29% of peers
Bars: peers in each 10-point band of the valuation score3 peers with a valuation score of 20–29, including IMCR · Click a bar to see the companies
Why valuation scores 29?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 68% of peers. EBITDA yield: 0.1% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.2% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -2.7% vs peer median 0.0%
Metric by metric
Position: dot = IMCR, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | IMCR | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 437 reported | -1.2% | 1.4% | 36% | 30% | |
| EBITDA yieldHigher is better · 450 reported | 0.1% | 4.3% | 30% | 50% | |
| Free cash flow yieldHigher is better · 205 reported | -2.7% | -0.5% | 42% | 20% | |
| Book yieldHigher is better · 439 reported | 27.2% | 38.6% | 35% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around IMCRScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score